Results: 1-15 |
Results: 15

Authors: Dalbagni, G Ren, ZP Herr, H Cordon-Cardo, C Reuter, V
Citation: G. Dalbagni et al., Genetic alterations in TP53 in recurrent urothelial cancer: A longitudinalstudy, CLIN CANC R, 7(9), 2001, pp. 2797-2801

Authors: Eschwege, P de Ledinghen, V Camilli, T Kulkarni, S Dalbagni, G Droupy, S Jardin, A Benoit, G Weksler, BB
Citation: P. Eschwege et al., Cyclooxygenase-2: a new target for epithelial cancer treatments - Arachidonic acid and prostaglandins, inflammation and oncology, PRESSE MED, 30(10), 2001, pp. 508-510

Authors: Eschwege, P de Ledinghen, V Camilli, T Kulkarni, S Dalbagni, G Droupy, S Jardin, A Benoit, G Weksler, BB
Citation: P. Eschwege et al., Cyclooxygenase-2: a new target for epithelial cancer treatments - Cyclooxygenases, PRESSE MED, 30(10), 2001, pp. 511-514

Authors: Eschwege, P de Ledinghen, V Camilli, T Kulkarni, S Dalbagni, G Droupy, S Jardin, A Benoit, G Weksler, BB
Citation: P. Eschwege et al., Cyclooxygenase-3: a new target far epithelial cancer treatments - Cyclooxygenase inhibitors, PRESSE MED, 30(10), 2001, pp. 515-517

Authors: Dalbagni, G Donat, SM Eschwege, P Herr, HW Zelefsky, MJ
Citation: G. Dalbagni et al., Results of high dose rate brachytherapy, anterior pelvic exenteration and external beam radiotherapy for carcinoma of the female urethra, J UROL, 166(5), 2001, pp. 1759-1761

Authors: Dalbagni, G Genega, E Hashibe, M Zhang, ZF Russo, P Herr, H Reuter, V
Citation: G. Dalbagni et al., Cystectomy for bladder cancer: A contemporary series, J UROL, 165(4), 2001, pp. 1111-1116

Authors: Dalbagni, G Cordon-Cardo, C Sheinfeld, J
Citation: G. Dalbagni et al., Current prospects for the use of molecular markers in treatment of bladdercancer by cystectomy or bladder-conserving approaches, CURR CLIN U, 2001, pp. 381-392

Authors: Dalbagni, G Herr, HW
Citation: G. Dalbagni et Hw. Herr, Current use and questions concerning intravesical bladder cancer group forsuperficial bladder cancer, UROL CLIN N, 27(1), 2000, pp. 137

Authors: Rabbani, F Richon, VM Orlow, I Lu, ML Drobnjak, M Dudas, M Charytonowicz, E Dalbagni, G Cordon-Cardo, C
Citation: F. Rabbani et al., Prognostic significance of transcription factor E2F-1 in bladder cancer: Genotypic and phenotypic characterization, J NAT CANC, 91(10), 1999, pp. 874-881

Authors: Cozzi, PJ Bajorin, DF Tong, W Nguyen, H Scott, J Heston, WDW Dalbagni, G
Citation: Pj. Cozzi et al., Toxicology and pharmacokinetics of intravesical gemcitabine: A preclinicalstudy in dogs, CLIN CANC R, 5(9), 1999, pp. 2629-2637

Authors: Dalbagni, G Zhang, ZF Lacombe, L Herr, HW
Citation: G. Dalbagni et al., Male urethral carcinoma: Analysis of treatment outcome, UROLOGY, 53(6), 1999, pp. 1126-1132

Authors: Dalbagni, G Rechtschaffen, T Herr, HW
Citation: G. Dalbagni et al., Is transurethral biopsy of the bladder necessary after 3 months to evaluate response to bacillus Calmette-Guerin therapy?, J UROL, 162(3), 1999, pp. 708-709

Authors: Weinstein, RP Genega, EM Dalbagni, G
Citation: Rp. Weinstein et al., Splenosis mimicking transitional cell carcinoma, J UROL, 161(4), 1999, pp. 1281-1281

Authors: Rabbani, F Dalbagni, G Bastar, A Fair, WR
Citation: F. Rabbani et al., Nomograms to predict pathologic results of radical prostatectomy: Effect of neoadjuvant hormone therapy, MOL UROL, 2(3), 1998, pp. 143-150

Authors: Dalbagni, G Zhang, ZF Lacombe, L Herr, HW
Citation: G. Dalbagni et al., Female urethral carcinoma: an analysis of treatment outcome and a plea fora standardized management strategy, BR J UROL, 82(6), 1998, pp. 835-841
Risultati: 1-15 |